Rhodes Jason P sold DYN

June 24, 2026 · Form 4 insider transaction

Rhodes Jason P sold 19,973 shares of Dyne Therapeutics, Inc. at $21.02 per share, a transaction worth $419.8K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
19,973
Price
$21.02
Total value
$419.8K
RoleDirector
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJune 24, 2026
Filing dateJune 26, 2026
Shares owned after1,086,063
OwnershipIndirect
10b5-1 planYes
AmendedNo

Footnotes

Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.; The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive.; The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

View the original Form 4 on SEC EDGAR